Everybody Suddenly Has an Amylin Strategy
For a long time, the public conversation around obesity medications revolved around a familiar group of hormonal targets.
Now another category is attracting serious attention. Amylin. And the development pipeline is getting crowded.
Different companies are investigating different approaches, from selective amylin receptor agonists to combinations involving incretin signaling. But the programs are not interchangeable.
This is a snapshot of five programs from four developers and what their public documents show as of October 12, 2026. It is not a complete list of every amylin-related program.
Eli Lilly: Eloralintide and EloraTZP
The eloralintide program investigates selective amylin receptor agonism. A peer-reviewed Phase 2 trial in 263 adults without type 2 diabetes reported dose-dependent body-weight reductions over 48 weeks. [1]
Lilly has also announced Phase 2b findings for EloraTZP, an investigational combination of eloralintide and tirzepatide, in 367 adults with obesity or overweight and type 2 diabetes over 48 weeks. [5][6] That is a sponsor announcement, not a peer-reviewed publication.
The standalone Phase 3 program includes the registered ENLIGHTEN studies, such as ENLIGHTEN-1, which was recruiting at the verification date. [7] The standalone program and the combination program are separate research efforts. Lilly says Phase 3 trials of EloraTZP are planned to start in the fourth quarter of 2026. [5]
Status at verification: Standalone Phase 3 studies registered and recruiting. EloraTZP Phase 2b results announced September 30, 2026, with Phase 3 combination trials planned.
Novo Nordisk: Cagrilintide and CagriSema
Cagrilintide has been investigated as an amylin analogue, including in combination with semaglutide as CagriSema.
The combination has peer-reviewed Phase 3a results in adults without type 2 diabetes (3,417 participants, 68 weeks) and in adults with type 2 diabetes (1,206 participants, 68 weeks). [2][3] A cardiovascular outcomes study, REDEFINE 3, is registered with 7,101 participants and was active, not recruiting, at the verification date. [4]
Novo Nordisk reported that it submitted CagriSema to the US FDA in December 2025 and anticipated an FDA decision by late 2026. [12] A search of the FDA’s Drugs@FDA database for cagrilintide on October 12, 2026 returned no entry. [13]
Status at verification: Phase 3a results published. FDA submission made in December 2025, with a decision anticipated by late 2026 according to the company. Cardiovascular outcomes study active, not recruiting.
Novo Nordisk: Zenagamtide, Also Known as Amycretin
Zenagamtide represents another approach. It is a single investigational peptide designed to act on both GLP-1 and amylin receptors, which distinguishes it from combinations in which separate molecules are studied together.
On June 6, 2026, the company reported results from a 36-week Phase 2 dose-finding trial in 262 adults with type 2 diabetes. [10] These were sponsor-reported results and should be kept separate from complete peer-reviewed publications.
Novo Nordisk has since registered Phase 3 studies under the name AMAZE. One of them, AMAZE 9, tests once-daily oral zenagamtide in a planned 950 adults with obesity. It lists a start date of August 31, 2026 and was recruiting at the verification date. [21] Registration shows that late-stage research is under way. It does not show results.
Status at verification: Phase 2 results announced. Phase 3 AMAZE studies registered and recruiting, including a study of oral zenagamtide.
Roche and Zealand Pharma: Petrelintide
Petrelintide is another investigational amylin analogue. The ZUPREME-1 Phase 2 trial is registered with 493 adults with overweight or obesity and ran for 42 weeks of treatment. [8][11] The sponsor announced topline results on March 5, 2026. [8] On June 5, 2026, Zealand Pharma reported additional data at the American Diabetes Association Scientific Sessions: a mean weight reduction of up to 10.7% from baseline at week 42, compared with 1.7% on placebo, and nausea in 19.6% of participants on petrelintide versus 6.2% on placebo. [17] These are sponsor-reported results, not a peer-reviewed publication.
Roche has since registered three Phase 3 studies of petrelintide for weight management. Each lists a start date of September 30, 2026 and was recruiting at the verification date: one in adults without type 2 diabetes (a planned 3,900 participants), one in adults with type 2 diabetes (600) and one in adults with established cardiovascular disease (2,500). [18][19][20] Each registers percentage change in body weight at week 64 as its primary outcome. Registration describes planned research. It does not report results.
A registered Phase 2 study, ZYNERGY, will test petrelintide together with enicepatide in a planned 486 participants. [9] Its listed status was still not yet recruiting.
This shows how amylin research is expanding from standalone compounds into combination strategies.
Status at verification: Phase 2 results presented at a medical congress. Three Phase 3 studies registered and recruiting. ZYNERGY combination study registered, not yet recruiting.
AbbVie: ABBV-295
ABBV-295 is a long-acting investigational amylin analogue. On March 9, 2026, AbbVie announced topline results from a Phase 1 multiple ascending dose study in 76 adults, with treatment lasting 12 to 13 weeks. [14]
Phase 1 research has a different purpose from large Phase 3 trials. It is mainly designed to look at safety, tolerability and how a drug behaves in the body, so early findings need further investigation before broader conclusions can be drawn.
Status at verification: Phase 1 topline results announced. AbbVie says it plans continued development for chronic weight management.
Programs Not Covered Here
Other companies have disclosed amylin programs that this snapshot does not yet cover. Pfizer described a monthly amylin analogue candidate, MET-233i, when it announced its agreement to acquire Metsera in September 2025. [15] AstraZeneca presented early-stage data on an amylin receptor agonist, AZD6234, in November 2024, according to trade press. [16] Their current status was not verified for this article.
Why There Is No Meaningful Ranking Yet
Each program has its own study population, development stage, comparator and endpoints. Trial lengths in this snapshot range from about 12 weeks to 68 weeks, and some programs studied adults with type 2 diabetes while others did not.
Some programs have peer-reviewed late-stage research. Others rely mainly on sponsor-reported early-stage findings. Putting all their reported percentages into one ranking would ignore those differences.
This is a pipeline tracker, not a league table. The useful questions are about research progress, evidence quality, safety and what each program is designed to establish.
What to Watch Next
Several developments will shape this field: additional peer-reviewed results, the progress and outcomes of late-stage trials, new information about adverse events and discontinuations, and regulatory decisions.
A company starting a trial is news about research activity. A completed, interpretable trial is evidence about outcomes. Those are different milestones.
The Bottom Line
Amylin research has become a serious part of the obesity drug-development landscape. The pipeline includes multiple compounds, development strategies and clinical stages.
There is no credible basis for crowning a universal winner from unrelated studies. But there are plenty of programs worth tracking, which is why this tracker will need regular updates.
Further reading: Clinical development and Obesity drug pipeline
Editorial note
This article discusses investigational drug research for educational purposes. It does not provide medical advice, treatment recommendations, or instructions for obtaining or administering experimental compounds. Clinical findings should be interpreted within their original study populations and methodological limitations.